

Scientific Advisory Board



Jeff Morhet, Chairman and Chief Executive Officer, holds vast experience in the pharmaceutical biotechnology industry, including positions at Baxter Healthcare, Merck and AstraZeneca. He has extensive experience with pharmaceutical product development, manufacturing, regulatory affairs, product commercialization and working with the FDA for both drug and device applications.



Thomas Kindt, Ph.D., Chief Scientific Officer, was most recently Director of Intramural Research, NIAID, NIH, Bethesda, MD and Chief of the Laboratory of Immunogenetics, NIAID, NIH. He has authored and co-authored 225 publications, two books and three patents. Currently, Tom is an active biomedical consultant, immunology textbook author and adjunct Professor at the University of New Mexico's Department of Biology.



Jur Strobos, M.D., J.D., Vice President, Clinical & Regulatory Affairs, brings with him extensive experience as Director of Policy Research in the office of the Commissioner of the Food and Drug Administration (FDA) and has a diverse background in drug law, medical product development, and health care. Most recently, he was Vice President of Clinical Research and Regulatory Affairs for Medicis Pharmaceutical Corporation.



Ronald Levy, M.D. earned his AB in Biochemistry at Harvard University and received his MD at Stanford University School of Medicine. Ronald has earned many professional accreditations, serving as the Robert K. Summy and Helen K. Summy Professor at Stanford and the Frank and Else Schilling American Cancer Society Clinical Research Professor. Ronald is the author of more than 250 articles that have appeared in various publications and peer-reviewed journals. He currently serves as the Stanford University School of Medicine Chief of the Division of Oncology.



Daniel D. Von Hoff, MD, FACP, is EVP of TGen, Director of TGen's Translational Drug Development Division and Head of TGen's Pancreatic Cancer Research Program. He is also Professor of Medicine, Molecular and Cellular Biology and Pathology at the University of Arizona and served as director of the Arizona Cancer Center. He is also Chief Scientific Officer for U.S. Oncology. Dan is past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology.



J. Donald Capra, M.D., serves as President Emeritus of the Oklahoma Medical Research Foundation (OMRF). He brings a wealth of research, discovery and business to the InNexus Team. He has made major discoveries in the field of antibody structure and genetics. Donald has been instrumental in defining the association of Immunoglobulin hypervariable regions with the antibody combining site.



Martin Weigert, Ph.D. received his BA in Biology from Haverford College and his Ph.D. in Biophysics from the University of Pennsylvania. Martin has held numerous positions of honor in research during his professional experience, including the Henry L. Hillman professor of Life Sciences, Dept. of Molecular Biology, Princeton University. He is a senior member of The Institute for Cancer Research; Member, Basel Institute for Immunology; Professor of Human Genetics, University of Pennsylvania; Research Associate, Salk Institute for Biological Studies, La Jolla, California.



Maurizio Zanetti, M.D. is a professor with the University of California, San Diego, Department of Medicine, Tumor Growth, Invasion & Metastasis Program and a member of the Cancer Center and the Center for AIDS Research. He received his undergraduate degree in Classical Studies from Lyceum Marcantonio Flaminio of Vittorio Veneto in Treviso, Italy. He belongs to numerous honorary and professional organizations, including Associate Editor of The Journal of Immunology and Cellular Immunology and a member of the American Society of Clinical Investigation and Clinical Immunology Society.



John D. Minna, M.D. is Director of the Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research and the W.A. "TeS" and Deborah Moncrief, Jr. Center for Cancer Genetics at the University of Texas Southwestern Medical Center at Dallas. He holds the Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology and the Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research. He received his undergraduate and medical degrees from Stanford University.



Judith James, Ph.D. received her Medical Degree and Ph.D. in Immunology from the Oklahoma Health Sciences Center and is board certified in Internal Medicine and Rheumatology. Dr. James has made seminal contributions to understanding how autoimmune diseases start and the concept of humeral epitope spreading. She continues to practice adult rheumatology, focusing on rheumatic diseases.



Ellen S. Vitetta, Ph.D. is an immunologist who performs translational "bench to bedside" research. Ellen has published 475 papers, edited several books, and is co-inventor on 13 issued patents. Over the past two decades Dr. Vitetta has developed antibody-based "biological missiles" (immunotoxins) to destroy cancer cells and cells infected with HIV. She is among the most cited biomedical scientists and the 10 most cited women of the past several decades. She has been the recipient of the Pierce Immunotoxin Award, and NIH Merit Award, 16 Faculty Teaching Awards, and the FASEE excellent in Science Award, among many others.



Carlos L. Arteaga, M.D. is Professor of Medicine and Cancer Biology and Director of the Breast Cancer Research Program of the Vanderbilt-Ingram Cancer Center at Vanderbilt University School of Medicine. He is also Director of the Breast Cancer Research Program and Breast Cancer SPORE of the NCI-designated Vanderbilt-Ingram Comprehensive Cancer Center. His research focuses on the role of growth factor receptors in the progression of breast cancer, as well as, the development of anti-cancer molecular therapeutics.